HCPCS code J0710 – Injection, cephapirin sodium

Key takeaways

HCPCS Code J0710 is the deleted Level II code for injection of cephapirin sodium, up to 1 gram, given parenterally.

The code is no longer active for billing. Claims filed under J0710 for current dates of service are denied by Medicare and most payers.

J3490 is the primary crosswalk for cephapirin sodium, and it needs a drug narrative covering dose, route and NDC.

Practice management software like Pabau submits claims electronically, checks required fields before submission, and tracks each claim through five status stages.

HCPCS Code J0710: definition and code details

HCPCS Code J0710 is a Level II National Code maintained by CMS under the HCPCS code set. The official descriptor reads: Injection, cephapirin sodium, up to 1 gm. It sits in the J-series, which covers drugs given by injection in physician office and outpatient settings under Medicare Part B.

Cephapirin sodium is a first-generation cephalosporin antibiotic. The beta-lactam compound is given parenterally, either intravenously or intramuscularly. It treated serious bacterial infections in settings where oral antibiotics were not an option. The billing unit of up to 1 gram set the threshold per administration, so doses above 1 gram took multiple units.

Why the code was deleted

HCPCS Code J0710 carries a deleted status in the CMS code file. Deleted means the code is no longer recognized for billing on current dates of service.

The HCPCS National Panel retires a J-series drug code for one of three reasons:

• The drug is withdrawn from the US market.
• Its commercial availability falls below the threshold for keeping a dedicated code.
• CMS consolidates the drug into an existing unclassified code category.

Cephapirin sodium’s limited market presence in the United States is why J0710 was retired. The drug is not widely available for physician office or outpatient use. That removed the need for a dedicated billing code.

One nuance matters for older encounters. If a claim carries a date of service from when J0710 was still active, some payers may still process the original code. MAC guidance varies here. Verify with your Medicare Administrative Contractor before you submit a retroactive claim under a deleted code.

Crosswalk and replacement codes

When a dedicated J-code is deleted, CMS routes claims through the unclassified drug code. J3490 covers any injectable drug with no assigned HCPCS code. It is not tied to one product, so the payer has to be told what was given.

Three routes cover almost every cephapirin sodium claim, and the date of service picks between them.

Payer acceptance of J3490 is not automatic. Most Medicare Administrative Contractors and commercial payers require supporting documentation when an unclassified code is submitted.

That documentation names the drug, the dosage, and the route of administration. It goes on the claim itself or travels as an attachment. Without it, the claim is held for additional development or denied.

When using J3490, AAPC coding guidance recommends a narrative description in Box 19 of the CMS-1500 form. The equivalent field in your 837P transaction does the same job. The narrative should state the drug name, the strength administered, the route, and the NDC number where available. Omitting any of these raises the chance of a medical review request.

Medicare billing rules for J0710

Under Medicare Part B, injectable drugs given in outpatient settings and physician offices are paid on Average Sales Price (ASP). A percentage add-on sits on top of that. J0710 is deleted, so no current Medicare rate is attached to it. The CMS ASP drug pricing files list rates for active J-codes only.

For claims submitted under J3490 as the crosswalk, Medicare payment is settled through individual payer review. Unclassified drug codes carry no assigned ASP rate, so the payer assesses cost from invoice or acquisition documentation. Keep acquisition cost invoices ready to submit alongside the claim.

Place of service matters too. Medicare Part B drug administration coverage differs by setting. Physician office (POS 11) and outpatient hospital (POS 22) claims run on distinct payment methodologies. Verify the POS code before submission, since a mismatch with the administered drug’s billing code is a common denial trigger.

Expect remittance advice on J3490 claims to carry remark codes about additional documentation or manual pricing review. Build a step into your billing process that flags these claims for follow-up within 30 days. The denial patterns for unclassified codes are predictable, which makes them correctable.

How to bill cephapirin sodium after J0710 deletion

Practices that still administer cephapirin sodium need a settled billing workflow. The six steps below follow CMS policy for deleted drug J-codes.

1. Verify drug availability and clinical indication. Confirm cephapirin sodium is available through your supplier and documented in the patient record, tied to a covered ICD-10 diagnosis code.
2. Select J3490 as the billing code. J3490 covers cephapirin sodium on current dates of service — J0710 never belongs on a current encounter. Confirm the code is still active using the NLM HCPCS Level II lookup API or your billing software’s validation tool.
3. Document the drug specifics in the claim narrative. Box 19 of the CMS-1500 form, or the equivalent 837P loop, takes the drug name, dose, route, frequency, and NDC number. A charge sheet that already captures them keeps the narrative consistent.
4. Attach acquisition cost documentation. Medicare and many commercial payers may ask for an invoice showing what you paid for the drug — prepare it before submitting to avoid an additional development request.
5. Submit a clean claim and monitor the remittance. Track it through the ERA/835 cycle and flag any denial or remark code pointing to missing documentation or pricing under review. Clearinghouse submission catches formatting errors before the claim reaches the payer.
6. Appeal denials with supporting documentation. Read the denial reason code first. Most denials on unclassified drug codes clear once you appeal with the narrative description and the acquisition cost invoice — incomplete documentation, not the crosswalk itself, causes most of them.

The clinical record has to support the claim. The note should carry the drug name, dose, route, time administered, and the practitioner’s signature — payers auditing J3490 claims routinely pull records to check them.

Related HCPCS J-codes for antibiotic injections

Several injectable antibiotics have carried dedicated HCPCS codes over the years. The table below lists the ones closest to cephapirin sodium, with their current status. Check status in our HCPCS code index before you submit any J-code claim, because a code that was active last year may not be now.

First-generation cephalosporins like cefazolin kept their codes because they remain in widespread clinical use. Cephapirin sodium’s limited availability is what drove J0710’s deletion. If you are substituting a more available antibiotic in the same class, check for its own active code first. Defaulting to J3490 costs you documentation work you may not need.

How Pabau keeps unclassified drug claims moving

Billing an unclassified code by hand means one person holding the narrative requirements in their head. The drug name, dose, route and NDC have to reach the claim every time. A missing field usually surfaces only after the payer sends the claim back.

Practice management software like Pabau moves those checks earlier. Pabau’s claims management software validates required fields in the background before a claim goes out. Incomplete claims get caught at your desk rather than at the payer’s.

Each submitted claim then moves through five status stages. Your team can see where a J3490 claim is sitting without calling the payer. When remittance comes back, it lands against the same patient record that holds the encounter.

Conclusion

J0710 is retired, and putting it on a current claim guarantees a denial. J3490 is the way forward, paired with a complete drug narrative. Where the payer asks, add an acquisition cost invoice. What decides whether those claims pay is documentation discipline, not the crosswalk.

Set the checklist once and the denials stop being a surprise. That matters most for teams handling several unclassified drug codes across a busy outpatient schedule. Book a demo to see how Pabau tracks each claim from submission to remittance.

Frequently asked questions